Per accedir als documents amb el text complet, si us plau, seguiu el següent enllaç: http://hdl.handle.net/2445/55264

Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer
Marin-Aguilera, M.; Codony-Servat, J.; Reig, O.; Lozano, JJ.; Fernández, PL.; Pereira, MV.; Jimenez, N.; Donovan, M.; Puig, P.; Mengual Brichs, Lourdes; Bermudo, R.; Font, A.; Gallardo, E.; Ribal, María José; Alcaraz Asensio, Antonio; Gascon, P.; Mellado González, Begoña
Universitat de Barcelona
Molecular characterization of radical prostatectomy specimens after systemic therapy may identify a gene expression profile for resistance to therapy. This study assessed tumor cells from patients with prostate cancer participating in a phase II neoadjuvant docetaxel and androgen deprivation trial to identify mediators of resistance. Transcriptional level of 93 genes from a docetaxel-resistant prostate cancer cell lines microarray study was analyzed by TaqMan low-density arrays in tumors from patients with high-risk localized prostate cancer (36 surgically treated, 28 with neoadjuvant docetaxel þ androgen deprivation). Gene expression was compared between groups and correlated with clinical outcome. VIM, AR and RELA were validated by immunohistochemistry. CD44 and ZEB1 expression was tested by immunofluorescence in cells and tumor samples. Parental and docetaxel-resistant castration-resistant prostate cancer cell lines were tested for epithelial-to-mesenchymal transition (EMT) markers before and after docetaxel exposure. Reversion of EMT phenotype was investigated as a docetaxel resistance reversion strategy. Expression of 63 (67.7%) genes differed between groups (P < 0.05), including genes related to androgen receptor, NF-k B transcription factor, and EMT. Increased expression of EMT markers correlated with radiologic relapse. Docetaxel-resistant cells had increased EMT and stem-like cell markers expression. ZEB1 siRNA transfection reverted docetaxel resistance and reduced CD44 expression in DU-145R and PC-3R. Before docetaxel exposure, a selected CD44 þ subpopulation of PC-3 cells exhibited EMT phenotype and intrinsic docetaxel resistance; ZEB1/CD44 þ subpopulations were found in tumor cell lines and primary tumors; this correlated with aggressive clinical behavior. This study identifies genes potentially related to chemotherapy resistance and supports evi-dence of the EMT role in docetaxel resistance and adverse clinical behavior in early prostate cancer.
Càncer de pròstata
Assaigs clínics
Medicaments antineoplàstics
Prostate cancer
Clinical trials
Antineoplastic agents
(c) American Association for Cancer Research, 2014
Article
info:eu-repo/semantics/acceptedVersion
American Association for Cancer Research
         

Mostra el registre complet del document

Documents relacionats

Altres documents del mateix autor/a

Marin-Aguilera, M.; Codony-Servat, J.; Reig, O.; Lozano, JJ.; Fernández, PL.; Pereira, MV.; Jimenez, N.; Donovan, M.; Puig, P.; Mengual Brichs, Lourdes; Bermudo, R.; Font, A.; Gallardo, E.; Ribal, María José; Alcaraz Asensio, Antonio; Gascon, P.; Mellado González, Begoña
Mateo González, Francesca; Meca-Cortés, Oscar; Celià-Terrassa; Fernández Amurgo, Yolanda; Abasolo, Ibane; Sánchez-Cid, Lourdes; Bermudo Gascón, Raquel; Sagasta, Amaia; Rodríguez-Carunchio,Leonardo; Pons, Mònica; Cánovas, Verónica; Marín Aguilera, Mercedes; Mengual Brichs, Lourdes; Alcaraz Asensio, Antonio; Schwartz Navarro, Simó; Mellado González, Begoña; Aguilera, Kristina Y.; Brekken, Rolf; Fernández Ruiz, Pedro Luis; Paciucci Barzanti, Rosanna; Thomsom, Timothy M.
Miyake, M.; Lawton, A.; Dai, Y.; Chang, M.; Mengual Brichs, Lourdes; Alcaraz Asensio, Antonio; Goodison, S.; Rosser, CJ.
Miyake, M.; Lawton, A.; Dai, Y.; Chang, M.; Mengual Brichs, Lourdes; Alcaraz Asensio, Antonio; Goodison, S.; Rosser, CJ.
Miyake, M.; Ross, S.; Lawton, A.; Chang, M.; Dai, Y.; Mengual Brichs, Lourdes; Alcaraz Asensio, Antonio; Giacoia, E.G.; Goodison, S.; Rosser, C.J.